RXST on Nasdaq

RxSight, Inc.

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with STAAR SURGICAL CO, Warby Parker or National Vision Holdings, Inc., or pick any stock.

  • TickerRXST on Nasdaq1
  • IndustryOphthalmic Goods1
  • HeadquartersAliso Viejo, California1
  • Incorporated inDE2
  • Business address100 Columbia Street, Suite 120, Aliso Viejo, Ca 926562
  • Filer categoryAccelerated filer2

See how the biggest companies compare on our leaderboards

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight ® Light Adjustable Lens system (“RxSight system”) is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens ® (LAL ® /LAL+ ® , collectively the “LAL”), RxSight Light Delivery Device (“LDD™”) and related accessories. The LAL is a premium intraocular lens (“IOL”) made from the proprietary silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet (“UV”) light patterns generated by the LDD.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

76.6%Gross margin4
-35.8%Operating margin4
-29.0%Net margin4
-3.9%Revenue growth, 20254
-14.1%Return on equity4
-$19.3MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

RxLAL brought in 80% of the revenue RxSight, Inc. broke down this way in fiscal 2025.

  1. RxLAL$108.1M480%up 12% from 2024
  2. LDD$20.7M415%down 48% from 2024
  3. Service Warranty Service Contracts And Accessories$5.7M44%up 54% from 2024
Products and services by year
Products and services202320242025
RxLAL$54.1M$96.5M$108.1M
LDD$32.1M$39.7M$20.7M
Service Warranty Service Contracts And Accessories$2.9M$3.7M$5.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue17¢$31.5M
  • Research and development21¢$38.5M
  • Selling, general and admin62¢$112.7M
  • Interest0¢$19.0K
  • Income tax0¢$66.0K

Out of $134.5M in revenue.4 The company lost money this year.

Financial statements

Revenue5674$134.5M in 2025+816% since 2020
0$50.0M$100.0M$150.0M2020: $14.7M$14.7M20202021: $22.6M$22.6M2021+54%2022: $49.0M$49.0M2022+117%2023: $89.1M$89.1M2023+82%2024: $139.9M$139.9M2024+57%2025: $134.5M$134.5M2025−4%
Gross profit5674$103.0M in 2025+5942% since 2020
0$50.0M$100.0M$150.0M2020: $1.7M$1.7M20202021: $4.5M$4.5M2021+165%2022: $21.3M$21.3M2022+372%2023: $53.8M$53.8M2023+152%2024: $98.9M$98.9M2024+84%2025: $103.0M$103.0M2025+4%
Operating income5674-$48.2M in 2025+36% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$35.4M-$35.4M20202021: -$52.8M-$52.8M2021+49%2022: -$63.3M-$63.3M2022+20%2023: -$50.1M-$50.1M2023−21%2024: -$36.9M-$36.9M2024−26%2025: -$48.2M-$48.2M2025+31%
Net income5674-$38.9M in 2025
-$75.0M-$50.0M-$25.0M0$25.0M$50.0M2020: $27.6M$27.6M20202021: -$48.7M-$48.7M20212022: -$66.8M-$66.8M2022+37%2023: -$48.6M-$48.6M2023−27%2024: -$27.5M-$27.5M2024−44%2025: -$38.9M-$38.9M2025+42%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Sales$134.5M$139.9M$89.1M
Cost of sales$31.5M$41.0M$35.3M
Gross profit$103.0M$98.9M$53.8M
Selling, general and administrative$112.7M$101.4M$74.8M
Research and development$38.5M$34.4M$29.1M
Total operating expenses$151.2M$135.8M$103.8M
Loss from operations-$48.2M-$36.9M-$50.1M
Interest expense-$19.0K-$21.0K-$3.3M
Interest and other income$9.3M$9.5M$6.6M
Loss on extinguishment of term loan$0$0-$1.8M
Loss before income taxes-$38.9M-$27.4M-$48.6M
Income tax expense$66.0K$50.0K$20.0K
Net loss-$38.9M-$27.5M-$48.6M
Unrealized (loss) gain on short-term investments-$136.0K$180.0K$83.0K
Foreign currency translation gain (loss)$23.0K-$9.0K$7.0K
Total other comprehensive (loss) income-$113.0K$171.0K$90.0K
Comprehensive loss-$39.1M-$27.3M-$48.5M
Attributable to common stock, basic-$0.95-$0.71-$1.41
Attributable to common stock, diluted-$0.95-$0.71-$1.41
Attributable to common stock, basic40.9M shares38.9M shares34.5M shares
Attributable to common stock, diluted40.9M shares38.9M shares34.5M shares

Compare RxSight, Inc. with another company

Leadership

Who has led RxSight, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ronald M. Kurtz Md.2023–2026
  2. Aziz Mottiwala2026–now

President

  1. Ronald M. Kurtz Md.2023–2026
  2. Aziz Mottiwala2026–now

Chief financial officer

  1. Shelley B. Thunen2021–2024
  2. Mark Wilterding2026–now

Chief operating officer

  1. Ilya Goldshleger2021–now
2025
Board members and other officers (18)

Former names

  • CALHOUN VISION INCJul 30, 2002 to Mar 20, 20142

Timeline

  1. Jul 24, 2026New chief executive Aziz Mottiwala becomes CEO11
  2. Feb 13, 2023New chief executive Ronald M. Kurtz Md. becomes CEO12

Filings

395 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 49 major events, 171 insider forms, 34 large holders, 120 other. The latest 20:

  1. Sep 16, 20264 EDGAR
  2. Sep 9, 20264 EDGAR
  3. Sep 9, 20264 EDGAR
  4. Sep 9, 20264 EDGAR
  5. Sep 9, 20264 EDGAR
  6. Sep 8, 2026SC TO-I/A EDGAR
  7. Sep 2, 2026144 EDGAR
  8. Sep 2, 2026144 EDGAR
  9. Sep 2, 2026144 EDGAR
  10. Sep 2, 2026144 EDGAR
  11. Sep 2, 20264 EDGAR
  12. Sep 2, 20264 EDGAR
  13. Sep 2, 20264 EDGAR
  14. Sep 2, 20264 EDGAR
  15. Aug 25, 2026SC TO-I/A EDGAR
  16. Aug 19, 2026SCHEDULE 13G EDGAR
  17. Aug 18, 2026144 EDGAR
  18. Aug 10, 2026SC TO-I EDGAR
  19. Aug 5, 202610-Q EDGAR
  20. Aug 5, 20268-K EDGAR

The 395 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

91 open-market trades by officers, directors and large owners since October 2021: 9 buys and 82 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 2, 2026Kurtz Ronald M MDChief Medical OfficerSale5,100$6.96$35.5KForm 4
Sep 2, 2026Wilterding MarkChief Financial OfficerSale7,765$6.96$54.0KForm 4
Sep 2, 2026Goldshleger IlyaChief Operating OfficerSale2,041$6.96$14.2KForm 4
Sep 2, 2026Weinberg EricSee remarksSale2,041$6.96$14.2KForm 4
Mar 12, 2025Fountain TamaraDirectorSale7,000$25.71$180.0KForm 4
Jan 22, 2025Maniar ShwetaDirectorSale3,519$30.87$108.6KForm 4
Jan 16, 2025Corley Jesse AndersonDirectorBuy1,767$31.13$55.0KForm 4
Jan 15, 2025Corley Jesse AndersonDirectorBuy1,443$31.19$45.0KForm 4
Nov 29, 2024Goldshleger IlyaChief Operating OfficerSale3,105$46.08$143.1KForm 4
Nov 26, 2024Maniar ShwetaDirectorSale3,782$45.88$173.5KForm 4
Nov 26, 2024Goldshleger IlyaChief Operating OfficerSale3,100$45.88$142.2KForm 4
Nov 22, 2024Goldshleger IlyaChief Operating OfficerSale3,100$45.00$139.5KForm 4
Nov 18, 2024Goldshleger IlyaChief Operating OfficerSale3,100$45.00$139.5KForm 4
Nov 15, 2024Goldshleger IlyaChief Operating OfficerSale4,875$46.00$224.2KForm 4
Nov 13, 2024Corley Jesse AndersonDirectorBuy11,365$44.92$510.5KForm 4
Nov 12, 2024Goldshleger IlyaChief Operating OfficerSale1,330$46.13$61.4KForm 4
Nov 12, 2024Corley Jesse AndersonDirectorBuy11,111$45.37$504.1KForm 4
Nov 7, 2024Goldshleger IlyaChief Operating OfficerSale3,100$55.00$170.5KForm 4
Nov 4, 2024Goldshleger IlyaChief Operating OfficerSale3,100$51.04$158.2KForm 4
Oct 30, 2024Goldshleger IlyaChief Operating OfficerSale3,105$51.91$161.2KForm 4

All 91 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.5,790,408$27.9M0.0%+2,603,316
Millennium Management LLC3,030,287$14.6M0.0%+970,828
No Street GP LP2,055,000$9.9M0.6%+55,000
Nomura Holdings Inc2,000,060$9.6M0.0%No change
D. E. Shaw & Co., Inc.1,985,215$9.6M0.0%+25,483
Vanguard Capital Management LLC1,675,582$8.1M0.0%−17,353
Aqr Capital Management LLC1,533,826$7.4M0.0%+897,697
Federated Hermes, Inc.1,201,195$5.8M0.0%+120,483
Two Sigma Investments, LP1,147,048$5.5M0.0%−153,212
Healthcare Of Ontario Pension Plan Trust Fund1,131,400$5.5M0.0%No change
UBS Group AG1,016,066$4.9M0.0%+776,610
Jacobs Levy Equity Management, Inc998,569$4.8M0.0%−67,752
Marshall Wace, Llp995,916$4.8M0.0%+983,191
Geode Capital Management, LLC984,978$4.7M0.0%+65,085
State Street Corp851,512$4.1M0.0%+50,189
Point72 Asset Management, L.P.778,252$3.8M0.0%+44,945
Grandeur Peak Global Advisors, LLC722,440$3.5M0.8%+256,848
Schonfeld Strategic Advisors LLC701,417$3.4M0.0%+509,717
Citadel Advisors LLC700,736$3.4M0.0%−417,983
Trexquant Investment LP607,935$2.9M0.0%+470,948
Goldman Sachs Group Inc546,154$2.6M0.0%+50,450
Deutsche Bank Ag\540,208$2.6M0.0%−422,104
Norges Bank500,000$2.4M0.0%New
Qube Research & Technologies Ltd491,550$2.4M0.0%+366,420
Bank Of America Corp /de/485,298$2.3M0.0%−724,741

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46